KR20140144255A - 생체관련 조성물 - Google Patents

생체관련 조성물 Download PDF

Info

Publication number
KR20140144255A
KR20140144255A KR1020147030491A KR20147030491A KR20140144255A KR 20140144255 A KR20140144255 A KR 20140144255A KR 1020147030491 A KR1020147030491 A KR 1020147030491A KR 20147030491 A KR20147030491 A KR 20147030491A KR 20140144255 A KR20140144255 A KR 20140144255A
Authority
KR
South Korea
Prior art keywords
bio
sodium
medium
composition
aqueous
Prior art date
Application number
KR1020147030491A
Other languages
English (en)
Korean (ko)
Inventor
메튜 루이스 스티븐 레이
스티브 레이
제니퍼 드레스맨
바스티안 클로에퍼
마르셀 아른드트
알렉산더 후크스
Original Assignee
파레스 파머수티컬 리서치 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파레스 파머수티컬 리서치 엔.브이. filed Critical 파레스 파머수티컬 리서치 엔.브이.
Publication of KR20140144255A publication Critical patent/KR20140144255A/ko

Links

Classifications

    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • G09B23/30—Anatomical models
    • G09B23/303—Anatomical models specially adapted to simulate circulation of bodily fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • G09B23/30—Anatomical models
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Computational Mathematics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Business, Economics & Management (AREA)
  • Mathematical Optimization (AREA)
  • Algebra (AREA)
  • Medical Informatics (AREA)
  • Mathematical Analysis (AREA)
  • Educational Administration (AREA)
  • Educational Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Fodder In General (AREA)
KR1020147030491A 2012-03-30 2013-04-02 생체관련 조성물 KR20140144255A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162548.7 2012-03-30
EP12162548.7A EP2645099A1 (en) 2012-03-30 2012-03-30 Biorelevant compositions
PCT/EP2013/056945 WO2013144374A1 (en) 2012-03-30 2013-04-02 Biorelevant compositions

Publications (1)

Publication Number Publication Date
KR20140144255A true KR20140144255A (ko) 2014-12-18

Family

ID=48143258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147030491A KR20140144255A (ko) 2012-03-30 2013-04-02 생체관련 조성물

Country Status (11)

Country Link
US (1) US20150064794A1 (pt)
EP (2) EP2645099A1 (pt)
JP (1) JP6348480B2 (pt)
KR (1) KR20140144255A (pt)
CN (1) CN104582689A (pt)
BR (1) BR112014024256A8 (pt)
CA (1) CA2867638A1 (pt)
IN (1) IN2014DN07927A (pt)
MX (1) MX357927B (pt)
NZ (1) NZ700064A (pt)
WO (1) WO2013144374A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ620040A (en) * 2011-08-23 2016-06-24 Kythera Biopharmaceuticals Inc Formulations of deoxycholic acid and salts thereof
WO2019199238A1 (en) * 2018-04-09 2019-10-17 Vet Products Research And Innovation Center Company Limited Inorganic mineral entrapped in nanoparticle production method thereof
GB201809627D0 (en) * 2018-06-12 2018-07-25 Biorelevant Com Ltd Methods for preparing buffer solutions suitable for in vitro drug dissolution testing, drug solubility testing and/or drug profiling
GB201904757D0 (en) * 2019-04-04 2019-05-22 Biorelevant Com Ltd Biorelevant composition
WO2021165386A1 (de) 2020-02-19 2021-08-26 Bayer Aktiengesellschaft Vorhersage von formulierungseigenschaften
GB202112975D0 (en) 2021-09-10 2021-10-27 Biorelevant Com Ltd Biorelevant dissolution compositions with reproducible spectral profiles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions
US6040188A (en) * 1997-11-18 2000-03-21 The Regents Of The University Of California In vitro gastrointestinal mimetic protocol for measuring bioavailable contaminants
IT1296914B1 (it) * 1997-12-01 1999-08-03 Maria Rosa Gasco Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera
WO2003042392A1 (en) * 2001-11-15 2003-05-22 Phares Pharmaceutical Research N.V. Standardised phospholipid mixtures
CA2560900A1 (en) * 2004-03-26 2005-10-06 Cell Therapeutics Europe S.R.L. Nanoparticle formulations of platinum compounds
GB0522942D0 (en) * 2005-11-10 2005-12-21 Leigh Steven Dissolution composition
PL1981516T3 (pl) * 2006-01-27 2019-03-29 Dupont Nutrition Biosciences Aps Zastosowanie mikroorganizmów probiotycznych w leczeniu i zapobieganiu otyłości i pokrewnym zaburzeniom
WO2008040799A2 (en) 2006-10-06 2008-04-10 Boehringer Ingelheim International Gmbh Process for preparing instant forms of aqueous mixed micellar solutions as physiological buffer systems for use in the analysis of in vitro release

Also Published As

Publication number Publication date
IN2014DN07927A (pt) 2015-05-01
CA2867638A1 (en) 2013-10-03
MX2014011789A (es) 2015-06-03
WO2013144374A1 (en) 2013-10-03
CN104582689A (zh) 2015-04-29
NZ700064A (en) 2016-08-26
BR112014024256A8 (pt) 2018-02-06
JP6348480B2 (ja) 2018-06-27
BR112014024256A2 (pt) 2017-06-20
JP2015524913A (ja) 2015-08-27
US20150064794A1 (en) 2015-03-05
MX357927B (es) 2018-07-27
EP2645099A1 (en) 2013-10-02
EP2830592A1 (en) 2015-02-04

Similar Documents

Publication Publication Date Title
KR20140144255A (ko) 생체관련 조성물
Boyd et al. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems
US8889189B2 (en) Dissolution composition for examining drug solubility
Roursgaard et al. In vitro toxicity of cationic micelles and liposomes in cultured human hepatocyte (HepG2) and lung epithelial (A549) cell lines
Xie et al. Micelle dynamic simulation and physicochemical characterization of biorelevant media to reflect gastrointestinal environment in fasted and fed states
Rabel et al. The differences of the impact of a lipid and protein corona on the colloidal stability, toxicity, and degradation behavior of iron oxide nanoparticles
Walsh et al. Comparing dog and human intestinal fluids: implications on solubility and biopharmaceutical risk assessment
US20220178900A1 (en) Biorelevant composition
US20220373446A1 (en) Biorelevant dissolution media
Gao Design and development of self-emulsifying lipid formulations for improving oral bioavailability of poorly water-soluble and lipophilic drugs
Jankovsky et al. Food effect risk assessment in preformulation stage using material sparing μFLUX methodology1
WO2014069651A1 (ja) Ｅｌ活性が関連する疾患の治療または予防効果を有する医薬の薬効評価方法及びｅｌ活性阻害物質のスクリーニング方法
WO2015025856A1 (ja) 標的物質とリガンドとの結合親和性を測定するための方法、ならびに該方法に使用するための試薬助剤およびキット
Raman Analysis of Surfactant-Mediated Dissolution Effects in Biorelevant Media
Tanaka et al. In Vitro Digestion–In Situ Absorption Setup Employing a Physiologically Relevant Value of the Membrane Surface Area/Volume Ratio for Evaluating Performance of Lipid-Based Formulations: A Comparative Study with an In Vitro Digestion–Permeation Model
WO2019143637A1 (en) Methods and compositions for quantifying hemoglobin
Rao et al. Comparative dissolution studies of marketed tablets of telmisartan in biorelevant media
Birru et al. Digestion of phospholipids after secretion of bile into the duodenum changes the phase behaviour of bile components and alters solubilisation capacity of bile salt-lipid mixed micelles

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application